ZimVie Shares Rise on FDA's Clearance of Prosthesis Portfolio
By Michael Susin
ZimVie shares rose on Tuesday after the group said it will launch its prosthesis portfolio in the U.S. following clearance from the Food and Drug Administration.
Shares were up 6.25% to $23.10 in premarket trading. The stock is up about 22% this year.
The company said its GenTek Genuine Restorative Component product portfolio received FDA's 510(k) clearance, meaning the prosthetic offerings can now be marketed in the U.S.
The company said the GenTek portfolio was initially launched in Europe in 2019 and saw a positive performance in that market to date.
"We have received excellent feedback and strong demand for GenTek in the European market, and we are optimistic that this product suite will be well received here in the U.S. -- the largest market we serve," Chief Commercial Officer Indraneel Kanaglekar said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
July 23, 2024 09:06 ET (13:06 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities